Đang chuẩn bị liên kết để tải về tài liệu:
Neo-adjuvant treatment of adenocarcinoma and squamous cell carcinoma of the cervix results in significantly different pathological complete response rates

Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ

Previous studies on cervical cancer reported a worse outcome for adenocarcinoma (AC) compared with squamous cell carcinoma (SCC). Nevertheless, standard treatment remains identical. | Neo-adjuvant treatment of adenocarcinoma and squamous cell carcinoma of the cervix results in significantly different pathological complete response rates

TÀI LIỆU LIÊN QUAN

The NeST (Neoadjuvant systemic therapy in breast cancer) study: National Practice Questionnaire of United Kingdom multi-disciplinary decision making

CEA clearance pattern as a predictor of tumor response to neoadjuvant treatment in rectal cancer: A post-hoc analysis of FOWARC trial

Novel biomarkers to predict treatment response and prognosis in locally advanced rectal cancer undergoing neoadjuvant chemoradiotherapy

Neoadjuvant FOLFOXIRI prior to chemoradiotherapy for high-risk (“ugly”) locally advanced rectal cancer: Study protocol of a single-arm, multicentre, open-label, phase II trial (MEND-IT)

GRP78 expression in peripheral blood mononuclear cells is a new predictive marker for the benefit of taxanes in breast cancer neoadjuvant treatment

Germline BRCA, chemotherapy response scores, and survival in the neoadjuvant treatment of ovarian cancer

Predictive factors of disease-free survival after complete pathological response to neoadjuvant radiotherapy for rectal adenocarcinoma: Retrospective case series

The value of GRASP on DCE-MRI for assessing response to neoadjuvant chemotherapy in patients with esophageal cancer

Mammographic density is a potential predictive marker of pathological response after neoadjuvant chemotherapy in breast cancer

RESPONDER – diagnosis of pathological complete response by vacuum-assisted biopsy after neoadjuvant chemotherapy in breast Cancer - a multicenter, confirmative, one-armed, intra-individually-controlled, open, diagnostic trial